In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium

International Journal of Antimicrobial Agents

Volumn 29, Issue 3, 2007, Pages 358-360

  Abb, Jochen ^a  

^a KLINIKUM LUDWIGSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; DRUG ACTIVITY; DRUG SENSITIVITY; ENTEROCOCCUS FAECIUM; HUMAN; IN VITRO STUDY; LETTER; PRIORITY JOURNAL;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; OXAZOLIDINONES; VIRGINIAMYCIN;

EID: 33846895977     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.10.007     Document Type: Letter

References (15)

1. Moellering R.C. Emergence of enterococcus as a significant pathogen. Clin Infect Dis 14 (1992) 1173-1178
2. Leclerc R., Derlot E., Duval J., and Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 319 (1988) 157-161
3. Murray B.E. Vancomycin-resistant enterococcal infections. N Engl J Med 342 (2000) 710-721
4. Huang M.B., Baker C.N., Banerjee S., and Tenover F.C. Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and Gram-negative bacteria resistant to antimicrobial agents. J Clin Microbiol 30 (1992) 3243-3248
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Supplement M100-S15. Wayne, PA: CLSI; 2005.
6. Pankey G.A. Tigecycline. J Antimicrob Chemother 56 (2005) 470-480
7. Cercenado E., Cercenado S., Gomez J.A., and Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 52 (2003) 138-139
8. Steenbergen J.N., Alder J., Thorne G.M., and Tally F.P. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55 (2005) 283-288
9. Jorgensen J.H., Crawford S.A., Kelly C.C., and Patterson J.E. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother 47 (2003) 3760-3763
10. Diekema D.J., and Jones R.N. Oxazolidinone antibiotics. Lancet 358 (2001) 1975-1982
11. Rybak M.J., Hershberger E., Moldovan T., and Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 44 (2000) 1062-1066
12. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., and Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
13. Chow J.W., Donabedian S.M., and Zervos M.J. Emergence of increased resistance to quinupristin-dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis 24 (1997) 90-91
14. Sabol K., Patterson J.E., Lewis II J.S., Owens A., Cadena J., and Jorgensen J.H. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 49 (2005) 1664-1665
15. Munoz-Price L.S., Lolans K., and Quinn J.P. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 41 (2005) 565